Premium
Luteinizing Hormone (LH) Surge in Patients Using Buserelin Spray during Ovarian Stimulation for Assisted Reproduction
Author(s) -
Ho PakChung,
Chan YuenFai,
So WaiKi,
Yeung William S. B.,
Chan Samuel T. H.
Publication year - 1993
Publication title -
asia‐oceania journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 0389-2328
DOI - 10.1111/j.1447-0756.1993.tb00367.x
Subject(s) - buserelin , luteinizing hormone , endocrinology , medicine , hormone , stimulation , agonist , receptor
Abstract The incidence of luteinizing hormone surge was studied in patients who were downregulated with a short protocol of gonadotrophin releasing hormone agonist before ovarian stimulation for assisted reproduction. Buserelin nasal spray 100 μg was given 5 times daily from day 2 of the cycle, followed by ovarian stimulation with human menopausal gonadotrophin and follicle stimulating hormone from day 3 onwards. Of the 159 cycles studied, luteinizing hormone surge was detected in 9 cycles (5.7%). The occurrence of LH surge was usually (67%) but not always associated with a fall in serum oestradiol level before administration of human chorionic gonadotrophin. None of the patients developed luteinizing hormone surge after day 10. Even in patients without luteinizing hormone surge the serum luteinizing hormone levels on the day of administration of hCG were significantly higher than those on day 2 before administration of buserelin. It is concluded that a short protocol with intranasal buserelin 500 μg per day is inadequate to suppress endogenous luteinizing hormone surge.